Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1282
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorDANILOVIC, Alexandre-
dc.contributor.authorLOPES, Roberto Iglesias-
dc.contributor.authorSANCHES, Talita Rojas-
dc.contributor.authorSHIMIZU, Maria Heloisa Massola-
dc.contributor.authorOSHIRO, Fabiola M.-
dc.contributor.authorANDRADE, Lucia-
dc.contributor.authorDENES, Francisco Tibor-
dc.contributor.authorSEGURO, Antonio Carlos-
dc.date.accessioned2013-07-30T17:17:35Z-
dc.date.available2013-07-30T17:17:35Z-
dc.date.issued2012-
dc.identifier.citationUROLOGY, v.80, n.2, article ID 485.e15, 6p, 2012-
dc.identifier.issn0090-4295-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1282-
dc.description.abstractOBJECTIVE To assess the effects of atorvastatin (ATORV) on renal function after bilateral ureteral obstruction (BUO), measuring inulin clearance and its effect on renal hemodynamic, filtration, and inflammatory response, as well as the expression of Aquaporin-2 (AQP2) in response to BUO and after the release of BUO. METHODS Adult Munich-Wistar male rats were subjected to BUO for 24 hours and monitored during the following 48 hours. Rats were divided into 5 groups: sham operated (n = 6); sham + ATORV (n = 6); BUO (n = 6); BUO + ATORV (10 mg/kg in drinking water started 2 days before BUO [n = 5]; and BUO + ATORV (10 mg/kg in drinking water started on the day of the release of BUO [n = 5]). We measured blood pressure (BP, mm Hg); inulin clearance (glomerular filtration rate [GFR]; mL/min/100 g); and renal blood flow (RBF, mL/min, by transient-time flowmeter). Inflammatory response was evaluated by histologic analysis of the interstitial area. AQP2 expression was evaluated by electrophoresis and immunoblotting. RESULTS Renal function was preserved by ATORV treatment, even if initiated on the day of obstruction release, as expressed by GFR, measured by inulin clearance. Relative interstitial area was decreased in both BUO + ATORV groups. Urine osmolality was improved in the ATORV-treated groups. AQP2 protein expression decreased in BUO animals and was reverted by ATORV treatment. CONCLUSION ATORV administration significantly prevented and restored impairment in GFR and renal vascular resistance. Furthermore, ATORV also improved urinary concentration by reversing the BUO-induced downregulation of AQP2. These findings have significant clinical implication in treating obstructive nephropathy. UROLOGY 80: 485.e15-485.e20, 2012. (c) 2012 Elsevier Inc.-
dc.language.isoeng-
dc.publisherELSEVIER SCIENCE INC-
dc.relation.ispartofUrology-
dc.rightsrestrictedAccess-
dc.subject.otheratrial-natriuretic-peptide-
dc.subject.otherwater channels-
dc.subject.otherexpression-
dc.subject.othertransporters-
dc.subject.othernephropathy-
dc.subject.otherinhibition-
dc.subject.otherdiuresis-
dc.subject.otherfibrosis-
dc.subject.otherfailure-
dc.titleAtorvastatin Prevents the Downregulation of Aquaporin-2 Receptor After Bilateral Ureteral Obstruction and Protects Renal Function in a Rat Model-
dc.typearticle-
dc.rights.holderCopyright ELSEVIER SCIENCE INC-
dc.identifier.doi10.1016/j.urology.2012.02.021-
dc.identifier.pmid22503765-
dc.subject.wosUrology & Nephrology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.articlenumber485.e15-
hcfmusp.description.issue2-
hcfmusp.description.volume80-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84864628163-
hcfmusp.origem.idWOS:000307244200082-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAngulo JC, 2010, UROLOGY, V76, P301, DOI 10.1016/j.urology.2009.12.002-
hcfmusp.relation.referenceDanilovic A, 2005, INT BRAZ J UROL, V31, P436-
hcfmusp.relation.referenceDanilovic Alexandre, 2005, Int Braz J Urol, V31, P431-
hcfmusp.relation.referenceEpstein M, 2005, AM J KIDNEY DIS, V45, P2, DOI 10.1053/j.ajkd.2004.08.040-
hcfmusp.relation.referenceFrokiaer J, 1996, AM J PHYSIOL-RENAL, V270, pF657-
hcfmusp.relation.referenceGordon Morris, 2007, Urology, V69, DOI 10.1016/j.urology.2007.01.022-
hcfmusp.relation.referenceGULMI FA, 1995, J UROLOGY, V153, P1276, DOI 10.1016/S0022-5347(01)67585-2-
hcfmusp.relation.referenceJensen AM, 2009, AM J PHYSIOL-RENAL, V296, pF127, DOI 10.1152/ajprenal.90479.2008-
hcfmusp.relation.referenceJensen AM, 2006, AM J PHYSIOL-RENAL, V291, pF1021, DOI 10.1152/ajprenal.00387.2005-
hcfmusp.relation.referenceKamdar C, 2010, UROLOGY, V75, P853, DOI 10.1016/j.urology.2009.05.030-
hcfmusp.relation.referenceKAUKER ML, 1992, NEPHRON, V60, P281-
hcfmusp.relation.referenceKim SW, 2001, J AM SOC NEPHROL, V12, P2019-
hcfmusp.relation.referenceKlahr S, 2002, AM J PHYSIOL-RENAL, V283, pF861, DOI 10.1152/ajprenal.00362.2001-
hcfmusp.relation.referenceKuwabara N, 2006, UROLOGY, V67, P440, DOI 10.1016/j.urology.2005.09.028-
hcfmusp.relation.referenceLi CL, 2003, AM J PHYSIOL-RENAL, V284, pF155, DOI 10.1152/ajprenal.00272.2002-
hcfmusp.relation.referenceLi CL, 2001, AM J PHYSIOL-RENAL, V281, pF163-
hcfmusp.relation.referenceLiano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380-
hcfmusp.relation.referenceVaughan E Darracott Jr, 2004, J Urol, V172, P2563, DOI 10.1097/01.ju.0000144286.53562.95-
hcfmusp.relation.referenceMatsuda H, 2011, UROLOGY, V77, pe249-
hcfmusp.relation.referenceMichli E, 2007, J UROLOGY, V177, P781, DOI 10.1016/j.juro.2006.09.078-
hcfmusp.relation.referenceMurer L, 2004, J AM SOC NEPHROL, V15, P2705, DOI 10.1097/01.ASN.0000139689.94776.7A-
hcfmusp.relation.referenceMURPHY GP, 1966, J UROLOGY, V95, P636-
hcfmusp.relation.referenceNorregaard R, 2005, AM J PHYSIOL-RENAL, V289, pF322, DOI 10.1152/ajprenal.00061.2005-
hcfmusp.relation.referencePuri TS, 2010, AM J PHYSIOL-RENAL, V298, pF1024, DOI 10.1152/ajprenal.00384.2009-
hcfmusp.relation.referenceREYES AA, 1991, P SOC EXP BIOL MED, V197, P49-
hcfmusp.relation.referenceRyndin I, 2005, J UROLOGY, V173, P651, DOI 10.1097/01.ju.0000150532.61780.1f-
hcfmusp.relation.referenceShimizu MHM, 2008, NEPHROL DIAL TRANSPL, V23, P3067, DOI 10.1093/ndt/gfn237-
hcfmusp.relation.referenceShokeir AA, 2002, UROLOGY, V59, P506, DOI 10.1016/S0090-4295(01)01623-5-
hcfmusp.relation.referenceYang SX, 2010, J ENDOUROL, V24, P1721, DOI 10.1089/end.2009.0420-
hcfmusp.relation.referenceYano Y, 2009, AM J PHYSIOL-RENAL, V296, pF54, DOI 10.1152/ajprenal.90367.2008-
hcfmusp.relation.referenceYao Y, 2011, UROLOGY, V77, pe768-
dc.description.indexMEDLINE-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus6-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/12
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia


Files in This Item:
File Description SizeFormat 
art_DANILOVIC_Atorvastatin_Prevents_the_Downregulation_of_Aquaporin_2_Receptor_2012.PDF
  Restricted Access
publishedVersion (English)1.01 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.